Last reviewed · How we verify
NCT07171034
A Phase I Study of KLA318-2 Nanocrystal Injection
Phase 1 trial testing KLA318-2 Nanocrystal Injection in Healthy Participants in 48 participants. Currently enrolling.
31 May 2026
Quick facts
| Lead sponsor | Hunan Kelun Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 1 September 2025 |
| Primary completion | 31 May 2026 |
| Estimated completion | 31 May 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- KLA318-2 Nanocrystal Injection — full drug profile →
- Celebrex Capsule
Conditions studied
- Healthy Participants — all drugs for Healthy Participants →
Sponsor
Hunan Kelun Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 45, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety,tolerability and pharmacokinetics properties of KLA318-2 Nanocrystal Injection after a single intravenous injection in healthy participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07171034
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Participants
Currently open trials in the same condition.
- NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
- NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
- NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
- NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
- NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
Other Hunan Kelun Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07474545 — A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07240675 — Single-dose,First-in-human of KLA478 · Phase 1 · recruiting
- NCT03050164 — Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions · Phase 1 · completed
- NCT03050177 — Bioequivalence Study of Gefitinib Tablets Under Fed Conditions · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07171034 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hunan Kelun Pharmaceutical Co., Ltd.
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07171034.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing